Cargando…

Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA

Therapeutic drug monitoring may be useful in tuberculosis management, but programmatic implementation is understudied. We performed a retrospective cohort study to determine prevalence of lower than expected levels of isoniazid, rifampin, ethambutol, and pyrazinamide measured at time of estimated pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Heysell, Scott K., Moore, Jane L., Keller, Suzanne J., Houpt, Eric R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3294393/
https://www.ncbi.nlm.nih.gov/pubmed/20875279
http://dx.doi.org/10.3201/eid1610.100374
_version_ 1782225489577902080
author Heysell, Scott K.
Moore, Jane L.
Keller, Suzanne J.
Houpt, Eric R.
author_facet Heysell, Scott K.
Moore, Jane L.
Keller, Suzanne J.
Houpt, Eric R.
author_sort Heysell, Scott K.
collection PubMed
description Therapeutic drug monitoring may be useful in tuberculosis management, but programmatic implementation is understudied. We performed a retrospective cohort study to determine prevalence of lower than expected levels of isoniazid, rifampin, ethambutol, and pyrazinamide measured at time of estimated peak serum concentration. Patients were tested for serum concentration at 2 hours after medication administration. When patients were tested, 22 had concentrations lower than expected range for rifampin, 23 of 39 patients had low levels of isoniazid, and 8 of 26 patients had low levels of ethambutol; all 20 patients tested for pyrazinamide were within expected range. Over 26 months, 42 patients met criteria for slow response. Diabetes was associated with slow response (p<0.001), and persons with diabetes were more likely than persons without diabetes to have low rifampin levels (p = 0.03). Dosage adjustment of rifampin was more likely to elevate serum concentration to the target range than adjustment of isoniazid given in daily doses (p = 0.01).
format Online
Article
Text
id pubmed-3294393
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-32943932012-03-08 Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA Heysell, Scott K. Moore, Jane L. Keller, Suzanne J. Houpt, Eric R. Emerg Infect Dis Research Therapeutic drug monitoring may be useful in tuberculosis management, but programmatic implementation is understudied. We performed a retrospective cohort study to determine prevalence of lower than expected levels of isoniazid, rifampin, ethambutol, and pyrazinamide measured at time of estimated peak serum concentration. Patients were tested for serum concentration at 2 hours after medication administration. When patients were tested, 22 had concentrations lower than expected range for rifampin, 23 of 39 patients had low levels of isoniazid, and 8 of 26 patients had low levels of ethambutol; all 20 patients tested for pyrazinamide were within expected range. Over 26 months, 42 patients met criteria for slow response. Diabetes was associated with slow response (p<0.001), and persons with diabetes were more likely than persons without diabetes to have low rifampin levels (p = 0.03). Dosage adjustment of rifampin was more likely to elevate serum concentration to the target range than adjustment of isoniazid given in daily doses (p = 0.01). Centers for Disease Control and Prevention 2010-10 /pmc/articles/PMC3294393/ /pubmed/20875279 http://dx.doi.org/10.3201/eid1610.100374 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Research
Heysell, Scott K.
Moore, Jane L.
Keller, Suzanne J.
Houpt, Eric R.
Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA
title Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA
title_full Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA
title_fullStr Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA
title_full_unstemmed Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA
title_short Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA
title_sort therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, virginia, usa
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3294393/
https://www.ncbi.nlm.nih.gov/pubmed/20875279
http://dx.doi.org/10.3201/eid1610.100374
work_keys_str_mv AT heysellscottk therapeuticdrugmonitoringforslowresponsetotuberculosistreatmentinastatecontrolprogramvirginiausa
AT moorejanel therapeuticdrugmonitoringforslowresponsetotuberculosistreatmentinastatecontrolprogramvirginiausa
AT kellersuzannej therapeuticdrugmonitoringforslowresponsetotuberculosistreatmentinastatecontrolprogramvirginiausa
AT houptericr therapeuticdrugmonitoringforslowresponsetotuberculosistreatmentinastatecontrolprogramvirginiausa